{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:07:37Z","timestamp":1771657657229,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vacunas"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vacun.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:04:49Z","timestamp":1648076689000},"page":"S67-S76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S2","title":["The prevalence of inverse health consequences of COVID-19 vaccines: A post-vaccination study"],"prefix":"10.1016","volume":"23","author":[{"given":"Yogendra","family":"Shrestha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Venkataraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vacun.2022.03.002_bb0005","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 vaccines: where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.vacun.2022.03.002_bb0010","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.vacun.2022.03.002_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife."},{"issue":"11","key":"10.1016\/j.vacun.2022.03.002_bb0020","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses","volume":"217","author":"Schmidt","year":"2020","journal-title":"J Exp Med"},{"issue":"April 2021","key":"10.1016\/j.vacun.2022.03.002_bb0025","article-title":"COVID-19 vaccine authorized in India-a mini-review","volume":"2","author":"Shrestha","year":"2021","journal-title":"SSRN Electron J"},{"key":"10.1016\/j.vacun.2022.03.002_bb0030","author":"Ministry of Health & Family Welfare, Division I"},{"issue":"1","key":"10.1016\/j.vacun.2022.03.002_bb0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jhep.2020.09.031","article-title":"COVID-19: discovery, diagnostics, and drug development","volume":"74","author":"Asselah","year":"2021","journal-title":"J Hepatol"},{"issue":"June","key":"10.1016\/j.vacun.2022.03.002_bb0040","first-page":"1","article-title":"Unraveling the mystery surrounding post-acute sequelae of COVID-19","volume":"12","author":"Ramakrishnan","year":"2021","journal-title":"Front Immunol"},{"issue":"10270","key":"10.1016\/j.vacun.2022.03.002_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)32656-8","article-title":"6-month consequences of COVID-19 in patients discharged from hospital: a cohort study","volume":"397","author":"Huang","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.vacun.2022.03.002_bb0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2020.12603","article-title":"Persistent symptoms in patients after acute COVID-19","volume":"324","author":"Carf\u00ec","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vacun.2022.03.002_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cmi.2020.09.023","article-title":"Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-center longitudinal study","volume":"27","author":"Xiong","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vacun.2022.03.002_bb0060","doi-asserted-by":"crossref","unstructured":"Peghin M, Palese A, Venturini M, Martino M De, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 27(1):1507\u201313.","DOI":"10.1016\/j.cmi.2021.05.033"},{"issue":"11","key":"10.1016\/j.vacun.2022.03.002_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bcr-2020-238419","article-title":"Sudden irreversible hearing loss post-COVID-19","volume":"13","author":"Koumpa","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"5","key":"10.1016\/j.vacun.2022.03.002_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines9050497","article-title":"Post-COVID syndrome: an insight on its pathogenesis","volume":"9","author":"Maltezou","year":"2021","journal-title":"Vaccines."},{"issue":"12","key":"10.1016\/j.vacun.2022.03.002_bb0075","first-page":"786","article-title":"Vaccine adverse events: separating myth from reality","volume":"95","author":"Spencer","year":"2017","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.vacun.2022.03.002_bb0080","first-page":"15","article-title":"Selected adverse events reported after COVID-19 vaccination what you need to know","author":"CDC","year":"2021","journal-title":"Vaccine."},{"key":"10.1016\/j.vacun.2022.03.002_bb0085","author":"EuroQol Research Foundation [Internet]"},{"key":"10.1016\/j.vacun.2022.03.002_bb0090","author":"mMRC (Modified Medical Research Council)"},{"issue":"10267","key":"10.1016\/j.vacun.2022.03.002_bb0095","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.vacun.2022.03.002_bb0100","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vacun.2022.03.002_bb0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11136-018-2003-4","article-title":"Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease","volume":"28","author":"Rencz","year":"2019","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.vacun.2022.03.002_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-016-0537-0","article-title":"Health-related quality of life measured using the EQ-5D\u20135L: South Australian population norms","volume":"14","author":"McCaffrey","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"24","key":"10.1016\/j.vacun.2022.03.002_bb0115","first-page":"3","article-title":"The Thai version of the EQ-5D-5L Health Questionnaire","volume":"3","author":"Pattanaphesaj","year":"2015","journal-title":"Heal Interv Technol Assess Progr"},{"issue":"7","key":"10.1016\/j.vacun.2022.03.002_bb0120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thx.54.7.581","article-title":"Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease","volume":"54","author":"Bestall","year":"1999","journal-title":"Thorax."},{"issue":"6","key":"10.1016\/j.vacun.2022.03.002_bb0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/vaccines9060673","article-title":"Safety of ChAdOx1 nCoV-19 vaccine: independent evidence from two EU states","volume":"9","author":"Riad","year":"2021","journal-title":"Vaccines."},{"issue":"22","key":"10.1016\/j.vacun.2022.03.002_bb0130","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/jcm10225338","article-title":"Self-reported adverse events of COVID-19 vaccines in Polish healthcare workers and medical students. Cross-sectional study and pooled analysis of CoVaST project results in Central Europe","volume":"10","author":"Dziedzic","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.vacun.2022.03.002_bb0135","doi-asserted-by":"crossref","first-page":"576","DOI":"10.7326\/M20-5661","article-title":"Sixty-day outcomes among patients hospitalized with COVID-19","volume":"174","author":"Chopra","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vacun.2022.03.002_bb0140","author":"Read"},{"key":"10.1016\/j.vacun.2022.03.002_bb0145","series-title":"COVID-19 natural immunity: scientific brief, 10 May 2021","author":"World Health Organization","year":"2021"}],"container-title":["Vacunas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1576988722000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1576988722000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:37:35Z","timestamp":1761622655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1576988722000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":29,"alternative-id":["S1576988722000310"],"URL":"https:\/\/doi.org\/10.1016\/j.vacun.2022.03.002","relation":{},"ISSN":["1576-9887"],"issn-type":[{"value":"1576-9887","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prevalence of inverse health consequences of COVID-19 vaccines: A post-vaccination study","name":"articletitle","label":"Article Title"},{"value":"Vacunas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vacun.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}